Exin Therapeutics
San Diego, USA· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing targeted therapies for neurodegenerative diseases by addressing protein aggregation pathways.
NeuroscienceNeurodegenerative Diseases
Technology Platform
A proprietary drug discovery platform targeting protein-protein interactions involved in neuronal aggregation pathologies. It utilizes structural biology and medicinal chemistry for CNS-penetrant compound design.
Opportunities
Potential to capture a multi-billion dollar market share with a first-in-class disease-modifying therapy for a major neurodegenerative condition.
Risk Factors
High risk of clinical failure inherent in neuroscience drug development, particularly in altering complex, poorly understood disease progression.
Competitive Landscape
Faces intense competition from large pharma and numerous biotechs pursuing amyloid, tau, and alpha-synuclein targets, with high clinical failure rates historically.